

Research Article

VEGFA-Enriched Exosomes from Tendon-Derived Stem Cells Facilitate Tenocyte Differentiation, Migration, and Transition to a Fibroblastic Phenotype

Zhaowen Xue,¹ Zihang Chen,¹ Tingting Wu,¹ Riwang Li,¹ Chao Chen,² Junting Liu,³ Huige Hou ¹, Xiaofei Zheng ¹, and Huajun Wang ¹

¹Department of Bone and Joint Surgery and Sports Medicine Center, The First Affiliated Hospital, Jinan University, Guangzhou 510630, China

²Department of Orthopedics, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China

³Department of Orthopedic Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China

Correspondence should be addressed to Huige Hou; 18620085802@126.com, Xiaofei Zheng; zhengxiaofei12@163.com, and Huajun Wang; whj220301@163.com

Received 8 June 2022; Revised 15 August 2022; Accepted 26 August 2022; Published 8 September 2022

Academic Editor: Valentina Russo

Copyright © 2022 Zhaowen Xue et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tendon-derived stem cells (TDSCs) play a vital role in repair of rotator cuff tear injuries by secreting paracrine proteins that regulate resident cell functions. Secreted exosomes may play a role in tendon injury repair by mediating intercellular communication; however, the detailed mechanisms by which TDSC-derived exosomes affect tenocyte development remain unknown. Here, we examined the effects of exosomes isolated from conditioned medium of TDSCs on tenocyte differentiation, migration, and transition to a fibroblastic phenotype *in vitro*. Successful isolation of exosomes from TDSCs was confirmed by high expression levels of CD81, CD63, CD9, and TSG101. Treatment with TDSC-derived exosomes promoted the growth and migration of cultured rat tenocytes, and increased the levels of the fibrosis markers collagen I, collagen III, scleraxis, tenascin C, and α -smooth muscle actin. Furthermore, vascular endothelial growth factor A (VEGFA) expression was higher in TDSC-derived exosomes than in TDSCs, and genetic knockdown of VEGFA suppressed the stimulatory effect of TDSC-derived exosomes on tenocyte development. Overall, these results demonstrate that VEGFA-enriched exosomes isolated from TDSCs promote differentiation and migration of cultured tenocytes and their transition to a fibroblastic phenotype. These data provide a new potential clinical treatment strategy for tendon injury.

1. Introduction

Rotator cuff tear (RCT) is one of the most common clinical injuries seen in orthopedic practice and sports medicine. The prevalence of RCT in various populations has been estimated to be approximately 20% [1, 2]. RCT is particularly common in elderly patients and can result in acute or chronic joint pain or other tissue injuries [3, 4]. In particular, RCT can cause substantial shoulder joint pain and dysfunction, and thereby impact an individual's quality of life and ability to work [5]. A variety of factors perturb RCT healing, including tendon degeneration, large tear size, and

advanced age [6–8]. The incidence of RCT rerupture is relatively high because of the incomplete healing of tendon bone injury; therefore, it is of great importance to explore the mechanisms underlying tendon injury and identify new strategies for clinical treatment.

Tenocytes and immature tenoblasts are the major cell types in tendon tissue. Mature tenocytes are typically quiescent, nondividing cells that synthesize collagen, extracellular matrix molecules, and other components [9]. Degradation of these cells has been reported in rotator cuff-related diseases [10], and tenocyte proliferation, migration, and fibrosis greatly contribute to tendon repair [11, 12]. Novel treatment

approaches for tendon injuries that aim to induce development of tenocytes into tenoligamentocytes have been reported [13].

Several donor cell types, including peripheral blood-derived mesenchymal stem cells (MSCs) [14], bone marrow-derived mesenchymal stem cells (BMSCs) [15, 16], dermal fibroblasts [17], and tenocytes [18], regulate tendon healing. Tendon-derived stem cells (TDSCs) can be isolated from tissues of humans and many other animals [19–21]. These precursor cells can differentiate into a variety of cell types, such as tenocytes, chondrocytes, osteocytes, and adipocytes [22]. Notably, TDSCs have a greater potential to generate tendon than other donor cells such as BMSCs [19, 21]. Application of donor cells directly to a lesion area has several limitations. For example, tenocytes produce a low level of collagen and exhibit poor differentiation [23], while BMSCs create ectopic bones and tumors [24].

Exosomes mediate cellular communication and molecular transport, and are crucial regulators of biological processes [25]. MSC-derived exosomes target the NLRP3 pathway to inhibit inflammatory responses in intervertebral disc degeneration [26] and have a potential application for tissue regeneration [27]. Thus, application of exosomes isolated from embryonic stem cells may be an effective method to treat tendon injury. However, there are few reports describing the targeting and regulation of tenocytes by TDSC-derived exosomes.

Vascular endothelial growth factor A (VEGFA), a member of the VEGF family of proteins, promotes angiogenesis, matrix formation, and collagen formation, all of which are important for tendon repair [28]. VEGFA in exosomes derived from stem cells is involved in a variety of bone functions and is reportedly upregulated in an animal model of osteoarthritis of the knee [29]. Notably, a recent study reported that VEGFA-enriched exosomes from cortical bone-derived MSCs stimulated by a CTRP9 polypeptide exert proangiogenic, antifibrotic, and cardioprotective effects [30]. However, whether VEGFA is enriched in TDSC-derived exosomes and its potential role in tenocyte function remain to be explored.

Here, we found that TDSC-derived exosomes are enriched with VEGFA and can regulate the migration, fibrotic activity, and proliferation of isolated rat tenocytes.

2. Materials and Methods

2.1. Ethics Statement and Animal Use. Sprague-Dawley (SD) rats were purchased from the Laboratory Animal Center of Jinan University, and the experiments were approved by the Ethics Committee of the First Affiliated Hospital, Jinan University. Rats were kept in a room with a light-controlled 12 h-12 h light-dark cycle, controlled room temperature (25°C), and unlimited food and water.

2.2. Isolation of Rat Tenocytes. Rotator cuff tendon tissues were isolated from SD rats as reported previously [31]. Tissues were sliced into small pieces, dispersed, and cultured in 6-well plates with Dulbecco's Modified Eagle Medium (DMEM, #11965092; Gibco, Waltham, MA, USA) supple-

mented with 10% fetal bovine serum (FBS, #10100147C, Gibco), 100 U/ml penicillin (#10378016, Gibco), and 100 U/ml streptomycin (#10378016, Gibco) in a humidified 5% CO₂ incubator at 37°C for 5 days. Following trypsinization, tenocytes were placed in DMEM containing 10% FBS and passaged three times before use.

2.3. Isolation of TDSCs. TDSCs were harvested from Achilles tendon tissues of SD rats as reported previously [32]. Briefly, rat Achilles tendons were isolated and then incubated with collagenase (Sigma, Carlsbad, CA, USA) for 2 h at 37°C before harvesting TDSCs. Isolated cells were plated in 100 mm dishes at a density of 200 cells/cm² and cultured in DMEM containing 20% FBS (Gibco), 100 U/ml penicillin, and 100 U/ml streptomycin (Gibco) in a standard tissue culture incubator for 10 days. Cells were passaged up to three times before use. TDSCs were identified as reported previously [32]. Expression of stem cell surface markers on TDSCs was measured by flow cytometry with antibodies against CD45 (ab40763; Abcam, Cambridge, UK), CD34 (ab81289, Abcam), CD90 (ab33694, Abcam), CD44 (12-0444-80; eBioscience, Thermo Fisher Scientific, MA, USA), and CD160 (ab274374, Abcam). The percentages of positive cells were measured with the FACScan system (Becton Dickinson, San Jose, CA, USA).

2.4. Isolation of TDSC-Derived Exosomes. To extract exosomes, after culture of TDSCs for 48 h, culture medium collected from 150 cm² dishes was centrifuged at 300×g for 20 min, 2000×g for 10 min, and 10,000×g for 60 min at 4°C. The supernatant was filtered with a 0.22 μm filter (Merck-Millipore, MA, USA), ultracentrifuged at 100,000×g for 1 h at 4°C, and resuspended in 200 μl phosphate-buffered saline. The morphology of isolated exosomes was assessed by transmission electron microscopy (TEM), and their size was measured using NanoSight viewer (Malvern Instruments, Malvern, UK). The concentration of exosomes (i.e., the protein concentration in exosomes) was measured using a BCA Protein Kit (#P0009; Beyotime, Shanghai, China). Western blotting with primary antibodies against the exosome markers TSG101 (ab125011), CD81 (ab109201), CD63 (ab108950), and CD9 (#ab92726, all from Abcam) was performed. Extracted exosomes (20 μg/ml) were added to the culture for treatment of tenocytes. The design of the procedures is shown in Figure 1(a).

2.5. Generation of Stable TDSCs. VEGFA-targeting shRNA sequences (shVEGFA) and a nonspecific shRNA (shNC) were subcloned into the lentiviral vector pLKO.1. HEK293 cells were transfected with the constructs for virus packaging. To remove cell debris from retrovirus-containing supernatants, 0.45 μm Millex-HV filters (Millipore,) were used. TDSCs were infected with a lentivirus harboring shVEGFA, shNC, or vector control to generate stable cell lines. For selection, cells were treated with 2 μg/ml puromycin (Sigma) for 48 h postinfection. The efficiency of VEGFA knockdown was determined by qPCR. The VEGFA shRNA sequences were 5'-GATCCGGCCAGCACATAGGAGTTC AAGAGAAGATTCAAGACGTCTCTCCTATGTGCTGG

CCTTTTTTGTGCGACA-3' (sense) and 3'-GCCGGTCGTGTATCCTCAAGTTCTTCTAAGTTCTGCAGAGAGGATACACGACCGGAAAAACAGCTGTTCTGA-5' (antisense) [33].

2.6. MTT Assay. Growth and proliferation of tenocytes were determined by an MTT assay. Briefly, tenocytes were seeded at a density of 1×10^4 /well into 96-well plates and cultured for the indicated duration. Subsequently, cells were treated with $50 \mu\text{l}$ of 2 mg/ml MTT at 37°C for 2 h. After dissolving formazan crystals, absorbance at 570 and 620 nm was measured using a Chameleon™ multitechnology microplate reader (Hidex, Turku, Finland).

2.7. Transwell Assay. A transwell system (Corning, Lowell, MA, USA) was used to monitor the migration ability of tenocytes. Cells were suspended in RPMI medium after transfection and cultured in the upper chamber. The lower chamber contained medium with exosomes from TDSCs or control (normal culture medium). The upper chamber surface was cleaned with a cotton swab after incubation for 24 h. Under an optical microscope (IX81; Olympus, Tokyo, Japan), migrated cells were assessed following staining with 0.1% crystal violet for 10 min. Five randomly selected images per well were captured with a microscope, and migrated cells were counted in a blinded manner.

2.8. RNA Isolation and Real-Time qPCR. The expression levels of mRNAs encoding collagen I, tenascin C (TnC), collagen III, scleraxis (Scx), α -smooth muscle actin (α -SMA), and VEGFA were determined by real-time qPCR. Briefly, TRIzol reagent (Sigma) was applied to extract total RNA, reverse transcription was performed with EasyScript cDNA Synthesis SuperMix (TransGen Biotech, Beijing, China), and real-time qPCR was performed with TransStart Top Green qPCR SuperMix (TransGen Biotech). Relative expression levels were determined using the $2^{-\Delta\Delta\text{Ct}}$ method, and GAPDH was used as the control. The primer sequences are shown in Table 1.

2.9. Western Blotting. Proteins in samples lysed using ice-cold RIPA buffer (Beyotime) containing protease inhibitors (Invitrogen, Carlsbad, USA) were separated by 10% SDS-PAGE and transferred to PVDF membranes (Millipore). After blocking in milk for 40 min, membranes were incubated with primary antibodies against collagen I (#ab34710), Scx (#ab58655), α -SMA (#ab32575), TnC (#ab108930), collagen III (#ab7778), GAPDH (#ab8245), and VEGFA (#ab46154, all from Abcam). Following incubation with a secondary antibody (Abclonal Biotechnology, Cambridge, MA, USA), bands were detected by enhanced chemiluminescence (Beyotime).

2.10. Statistical Analyses. Each experiment was performed in triplicate. Data were analyzed with SPSS (27.0) to determine the mean and standard deviation. When comparing unpaired samples, the Student's t-test was used to compare two groups and a one-way analysis of variance was used to compare the means among three or more groups. $P < 0.05$ was considered statistically significant.

3. Results

3.1. Generation and Identification of TDSC-Derived Exosomes. TDSCs were isolated from the Achilles tendons of SD rats and cultured. During culture, TDSCs displayed shuttle, spindle, and polygonal morphologies. Flow cytometry revealed that TDSCs highly expressed MSC markers, including CD90 (94.4%), CD44 (96.6%), and CD106 (97.3%) but not CD45 (0.3%) or CD34 (0.2%) (Figure 1(b)), as reported previously [34–36]. Exosomes were extracted from cultured TDSCs by ultracentrifugation. Their morphology and size were analyzed using TEM and NanoSight viewer, respectively. TEM showed that exosomes had a hollow spherical shape, and that their diameter was around 110 nm (Figure 1(c)). Western blotting showed that expression of the exosome markers CD9, CD81, CD63, and TSG101 was higher in the TDSC-derived exosome fraction than in the TDSC fraction (Figures 1(d) and 1(e)). These data suggest that exosomes were successfully isolated from conditioned medium of TDSCs.

3.2. TDSC-Derived Exosomes Promote Tenocyte Differentiation, Migration, and Transition to a Fibroblastic Phenotype. An MTT assay revealed that treatment with TDSC-derived exosomes significantly promoted growth of tenocytes (Figure 2(a)). In addition, a transwell assay revealed that the migration ability of tenocytes treated with TDSC-derived exosomes was superior to that of untreated tenocytes (Figures 2(b)–2(c)). The mRNA and protein levels of the fibrosis markers collagen I, collagen III, α -SMA, Scx, and TnC were determined in untreated and TDSC-derived exosome-treated tenocytes. The mRNA levels were significantly upregulated in tenocytes treated with TDSC-derived exosomes (Figures 2(d)). The protein levels showed the same trend as the mRNA levels (Figures 2(e) and 2(f)), indicating that treatment with TDSC-derived exosomes promotes the transition of tenocytes to a fibroblastic phenotype. Taken together, these data suggest that TDSC-derived exosomes regulate the differentiation and migration of tenocytes and their transition to a fibroblastic phenotype.

3.3. VEGFA Is Upregulated in TDSC-Derived Exosomes and Tenocytes Treated with these Exosomes. To elucidate the mechanism underlying the growth-promoting effect of TDSC-derived exosomes on tenocytes, we performed qPCR analyses of various genes in TDSC-derived exosomes and tenocytes treated with these exosomes. The mRNA and protein levels of VEGFA were markedly higher in TDSC-derived exosomes than in the control group (Figures 3(a)–3(c)). Furthermore, the mRNA and protein levels of VEGFA were markedly higher in tenocytes treated with TDSC-derived exosomes than in untreated tenocytes (Figures 3(d)–3(f)). These results suggest that VEGFA is upregulated in TDSC-derived exosomes and tenocytes treated with these exosomes.

3.4. Genetic Knockdown of VEGFA Abolishes the Effects of TDSC-Derived Exosomes on Tenocyte Differentiation, Migration, and Transition to a Fibroblastic Phenotype. To confirm the effect of exosomal VEGFA on tenocytes, we constructed a TDSC line in which VEGFA was knocked down using a lentiviral shRNA (shVEGFA, Figure 4(a)). A TDSC line expressing a nonspecific shRNA (shNC) was




FIGURE 1: Morphology and phenotypic identification of TDSCs and TDSC-derived exosomes. (a) Schematic presentation of the experimental design. (b) Flow cytometric analysis of cell surface markers of TDSCs. Red curves represent controls, and green curves represent surface markers. (c) TEM showing the morphology and size distribution of exosomes derived from TDSCs. Scale bar: 100 nm. (d) Western blot analyses of CD9, CD63, CD81, and TSD101 in exosomes isolated from cultured TDSCs. (e) Quantification of the expression levels of the proteins shown in (D). * $P < 0.05$ relative to TDSCs.

TABLE 1: Real-time qPCR primer sequences (5'-3').

Gene	Forward primer	Reverse primer
<i>Vegfa</i>	GCACATAGGAGAGATGAGCTTCC	CACGCCTTGGCTTGTCCACAT
<i>Scx</i>	AGCCCAAACAGATCTGCACCTT	CTTCCACCTTCACTAGTGGCATCA
<i>Collagen I</i>	GTCCGAGGTCCTAATGGAGATGC	GGTCCAGGGAATCCGATGT
<i>Collagen III</i>	ACAGCAGTCCAATGTAGATG	GAGCAGGTGTAGAAGGCTG
α -SMA	GAGGCACCACTGAACCCTAA	CATCTCCAGAGTCCAGCACA
<i>Tnc</i>	CGGGGCTATAGAACCAGT	AACATTTAAGTTTCCAATTCAGGTT
<i>Gapdh</i>	TGATTCTACCCACGGCAAGTT	TGATGGGTTTCCCATTTGATGA

generated as a control. Successful knockdown of VEGFA was confirmed by western blotting (Figure 4(b)). Exosomes were extracted from both these cell lines and added to tenocyte cultures. Exogenous VEGFA was added to tenocytes as a positive control. Treatment with VEGFA or exosomes derived from shNC-TDSCs significantly promoted the growth and migration of tenocytes (Figures 4(c)– 4(e)). However, knockdown of VEGFA abolished the stimulatory effect of TDSC-derived exosomes on growth (Figure 4(c)) and migration (Figures 4(d)–4(e)) of tenocytes. Furthermore, treatment of tenocytes with shNC-TDSC-derived exosomes or VEGFA significantly increased the levels of collagen I, α -SMA, collagen III, *Scx*, and *TnC*, whereas treatment with shVEGFA-TDSC-derived exosomes did not (Figures 4(g)– 4(h)). Overall, these results indicate that VEGFA promotes tenocyte growth, migration, and transition to a fibroblastic phenotype, and that the stimulatory effects of TDSC-derived exosomes on these behaviors of tenocytes are mediated via upregulation of VEGFA.

4. Discussion

Tenocytes play an important role in the repair of tendon injuries because they are the main cell type in tendon tissue. The results presented here demonstrate that TDSC-derived exosomes promote the growth and migration of rat tenocytes and their transition to a fibroblastic phenotype. VEGFA was upregulated in TDSC-derived exosomes and tenocytes treated with these exosomes, and silencing of VEGFA abolished the stimulatory effects of TDSC-derived exosomes on the behaviors of tenocytes. Taken together, these results suggest that VEGFA in TDSC-derived exosomes plays a novel role in regulating differentiation of tenocytes.

Exosomes isolated from various cell types can induce musculoskeletal tissue repair. For example, exosomes isolated from BMSCs promote myogenesis and muscle differentiation in a mouse injury model [37]. In addition, exosomes secreted during the transformation of myoblasts into myotubules promote myogenesis of adipose-derived stem cells and induce myofiber regeneration for injury repair [38]. Exosomes might also offer a novel way to treat osteoporosis. Exosomes derived from MSCs in a scaffold promote repair of bone defects via the PI3K/Akt pathway [39]. BMSC-derived exosomes improve osteoporosis by suppressing cell apoptosis and promoting osteoblast proliferation

[40, 41]. In addition, a recent study found that exosomes secreted by endothelial cells improve osteoporosis by inhibiting osteoclast activity, and that this effect is superior to that of BMSC-derived exosomes [42]. Furthermore, exosomes are related to cartilage regeneration and osteoarthritis. Embryonic MSC-derived exosomes induce cartilage repair by increasing chondrocyte proliferation, enhancing collagen production, and regulating immune reactivity [43, 44]. miR-100-5p in exosomes derived from fat pad MSCs maintains cartilage homeostasis by regulating the autophagy pathway [45].

In view of their superior clonogenicity and tenogenic proliferation potential, TDSCs were selected as an ideal source of exosomes to manipulate the function of tenocytes in the current study. Exosomes isolated from TDSCs promote the tenogenesis of resident TDSCs, and regulate synthesis and degradation of the tendon extracellular matrix [46]. TDSC-derived exosomes suppress inflammation in a model of Achilles tendon injury [47]. Moreover, TDSC-derived exosomes promote growth and migration by modulating the transforming growth factor signaling pathway and promote tendon repair through miR-144-3p in TDSCs [35]. Here, we found that high expression of VEGFA is responsible for the stimulatory effects of TDSC-derived exosomes on tenocyte proliferation, migration, and transition to a fibroblastic phenotype because shRNA-mediated knockdown of VEGFA abolished the ability of TDSC-derived exosomes to promote tenocyte development. VEGF is critical for bone tissue repair. Expression of VEGF is upregulated in injured leg bones of rats and cruciate ligaments of dogs [48]. In addition, during acute injury healing, BEGF and VEGF are upregulated at the bone-tendon junction [28]. Recently, high expression of VEGF in MSCs was reported to regulate repair of RCT via regulation of miR-205-5p [49]. In addition, induction of VEGFA expression by engineered nanoparticles promotes tendon healing. In our previous study, we showed that the long noncoding RNA H19 accelerates differentiation of rat tenocytes by inhibiting miR-140-5p, which leads to upregulation of VEGFA at the lesion site [31]. Expanding on this finding, we demonstrated here that upregulation of VEGFA in exosomes from TDSCs promotes tenocyte development. Taken together, these findings suggest that VEGFA plays a critical role in tendon differentiation and repair. However, the detailed mechanism by which VEGFA is upregulated in TDSC-derived exosomes and the role of these exosomes in RCT repair require further investigation.




FIGURE 2: Continued.




FIGURE 2: TDSC-derived exosomes promote tenocyte differentiation, migration, and transition to a fibroblastic phenotype. (a) An MTT assay to investigate the proliferation of tenocytes in the control (normal culture medium) and TDSC-derived exosome-treated groups. (b) A transwell assay to monitor the migration of tenocytes in the control and TDSC-derived exosome-treated groups. (c) Quantification of the transwell assay data shown in (B). The mRNA (d) and protein (E-F) levels of collagen I, collagen III, α-SMA, Scx, and TnC in control and TDSC-derived exosome-treated tenocytes determined by RT-qPCR and western blotting. * $P < 0.05$ relative to the control group.








FIGURE 3: VEGFA is upregulated in TDSC-derived exosomes and tenocytes treated with these exosomes. (A-C) The mRNA (A) and protein (B, C) levels of VEGFA in TDSCs and TDSC-derived exosomes determined by real-time qPCR and western blotting. (D-F) The mRNA (D) and protein (E, F) levels of VEGFA in control and TDSC-derived exosome-treated tenocytes determined by RT-qPCR and western blotting. * $P < 0.05$, ** $P < 0.01$ relative to TDSCs or the control tenocyte group.




(a)

(b)



(c)



(d)

FIGURE 4: Continued.




FIGURE 4: Genetic knockdown of VEGFA suppresses the stimulatory effects of TDSC-derived exosomes on tenocyte growth, migration, and transition to a fibroblastic phenotype. (A) TDSCs with VEGFA knockdown induced by a lentivirus and control TDSCs. (B) Knockdown of VEGFA determined by western blotting and quantification. Tenocytes were treated with VEGFA or exosomes derived from shVEGFA-TDSCs or shNC-TDSCs. (C) An MTT assay to investigate the growth of tenocytes. (D, E) A transwell assay to monitor the migration of tenocytes. (F–H) The mRNA (F) and protein (G, H) levels of collagen I, α-SMA, collagen III, Scx, and TnC determined by RT-qPCR and western blotting. * $P < 0.05$, ** $P < 0.01$ relative to the indicated group.

In summary, we demonstrated that VEGFA-enriched exosomes isolated from TDSCs promote growth and migration of rat tenocytes and their transition to a fibroblastic

phenotype. Further studies of TDSC-derived VEGFA-expressing exosomes may provide new insights into novel approaches for the clinical treatment of tendon injury.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The author(s) declare(s) that they have no conflicts of interest.

Funding

This work was supported by the National Natural Science Foundation of China (grant no. 82074511 and 81973660), the Project of Administration of Traditional Chinese Medicine of Guangdong Province of China (grant no. 20202040), and the Fundamental Research Funds for the Central Universities (grant no. 21620452).

References

- [1] H. Minagawa, N. Yamamoto, H. Abe et al., "Prevalence of symptomatic and asymptomatic rotator cuff tears in the general population: from mass-screening in one village," *Journal of Orthopaedics*, vol. 10, no. 1, pp. 8–12, 2013.
- [2] M. Abate, C. Schiavone, L. Di Carlo, and V. Salini, "Prevalence of and risk factors for asymptomatic rotator cuff tears in postmenopausal women," *Menopause*, vol. 21, no. 3, pp. 275–280, 2014.
- [3] E. Iwata, H. Shigematsu, K. Inoue et al., "Biceps-related physical findings are useful to prevent misdiagnosis of cervical Spondylotic Amyotrophy as a rotator cuff tear," *Asian Spine Journal*, vol. 12, no. 1, pp. 69–73, 2018.
- [4] N. J. Bureau, M. Deslauriers, M. Lepage-Saucier et al., "Rotator cuff tear morphologic parameters at magnetic resonance imaging: relationship with muscle atrophy and fatty infiltration and patient-reported function and health-related quality of life," *Journal of Computer Assisted Tomography*, vol. 42, no. 5, pp. 784–791, 2018.
- [5] R. C. Mather, L. Koenig, D. Acevedo et al., "The societal and economic value of rotator cuff repair," *The Journal of Bone and Joint Surgery. American Volume*, vol. 95, no. 22, pp. 1993–2000, 2013.
- [6] B. T. Le, X. L. Wu, P. H. Lam, and G. A. Murrell, "Factors predicting rotator cuff retears: an analysis of 1000 consecutive rotator cuff repairs," *The American Journal of Sports Medicine*, vol. 42, no. 5, pp. 1134–1142, 2014.
- [7] J. J. Barry, D. A. Lansdown, S. Cheung, B. T. Feeley, and C. B. Ma, "The relationship between tear severity, fatty infiltration, and muscle atrophy in the supraspinatus," *Journal of Shoulder and Elbow Surgery*, vol. 22, no. 1, pp. 18–25, 2013.
- [8] J. H. Oh, S. H. Kim, H. M. Ji, K. H. Jo, S. W. Bin, and H. S. Gong, "Prognostic factors affecting anatomic outcome of rotator cuff repair and correlation with functional outcome," *Arthroscopy*, vol. 25, no. 1, pp. 30–39, 2009.
- [9] P. Sharma and N. Maffulli, "Biology of tendon injury: healing, modeling and remodeling," *Journal of Musculoskeletal & Neuronal Interactions*, vol. 6, no. 2, pp. 181–190, 2006.
- [10] L. M. Schwab, P. Blanch, and M. Young, "Autologous tenocyte implantation into shoulder tendon pathology in an elite swimmer," *Physical Therapy in Sport*, vol. 29, pp. 19–25, 2018.
- [11] D. R. Berger, C. J. Centeno, and N. J. Steinmetz, "Platelet lysates from aged donors promote human tenocyte proliferation and migration in a concentration-dependent manner," *Bone & Joint Research*, vol. 8, no. 1, pp. 32–40, 2019.
- [12] X. Mao and Z. Yin, "Inhibition of miR-205 Promotes Proliferation, Migration and Fibrosis of Tenocytes through Targeting MECP2: Implications for Rotator Cuff Injury," *Advances in Clinical and Experimental Medicine*, vol. 31, no. 4, pp. 437–443, 2022.
- [13] A. Hoffmann and G. Gross, "Tendon and ligament engineering in the adult organism: mesenchymal stem cells and gene-therapeutic approaches," *International Orthopaedics*, vol. 31, no. 6, pp. 791–797, 2007.
- [14] E. Depuydt, S. Y. Broeckx, K. Chiers et al., "Cellular and humoral immunogenicity investigation of single and repeated allogeneic Tenogenic primed mesenchymal stem cell treatments in horses suffering from tendon injuries," *Frontiers in Veterinary Science*, vol. 8, article 789293, 2021.
- [15] H. A. Awad, G. P. Boivin, M. R. Dressler, F. N. Smith, R. G. Young, and D. L. Butler, "Repair of patellar tendon injuries using a cell-collagen composite," *Journal of Orthopaedic Research*, vol. 21, no. 3, pp. 420–431, 2003.
- [16] A. K. Chong, A. D. Ang, J. C. Goh et al., "Bone marrow-derived mesenchymal stem cells influence early tendon-healing in a rabbit achilles tendon model," *The Journal of Bone and Joint Surgery. American Volume*, vol. 89, no. 1, pp. 74–81, 2007.
- [17] D. Deng, W. Liu, F. Xu et al., "Engineering human neo-tendon tissue *in vitro* with human dermal fibroblasts under static mechanical strain," *Biomaterials*, vol. 30, no. 35, pp. 6724–6730, 2009.
- [18] J. M. Chen, C. Willers, J. Xu, A. Wang, and M. H. Zheng, "Autologous tenocyte therapy using porcine-derived bioscaffolds for massive rotator cuff defect in rabbits," *Tissue Engineering*, vol. 13, no. 7, pp. 1479–1491, 2007.
- [19] Y. Bi, D. Ehirchiou, T. M. Kilts et al., "Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche," *Nature Medicine*, vol. 13, no. 10, pp. 1219–1227, 2007.
- [20] Y. F. Rui, P. P. Lui, G. Li, S. C. Fu, Y. W. Lee, and K. M. Chan, "Isolation and characterization of multipotent rat tendon-derived stem cells," *Tissue Engineering. Part A*, vol. 16, no. 5, pp. 1549–1558, 2010.
- [21] J. Zhang and J. H. Wang, "Characterization of differential properties of rabbit tendon stem cells and tenocytes," *BMC Musculoskeletal Disorders*, vol. 11, no. 1, p. 10, 2010.
- [22] A. B. Lovati, B. Corradetti, A. Lange Consiglio et al., "Characterization and differentiation of equine tendon-derived progenitor cells," *Journal of Biological Regulators and Homeostatic Agents*, vol. 25, 2 Suppl, pp. S75–S84, 2011.
- [23] A. J. Almarza, S. M. Augustine, and S. L. Woo, "Changes in gene expression of matrix constituents with respect to passage of ligament and tendon fibroblasts," *Annals of Biomedical Engineering*, vol. 36, no. 12, pp. 1927–1933, 2008.
- [24] R. Tasso, A. Augello, M. Carida et al., "Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds," *Carcinogenesis*, vol. 30, no. 1, pp. 150–157, 2009.

- [25] J. Zhang, J. Zhang, Y. Zhang et al., "Mesenchymal stem cell-derived exosomes ameliorate intervertebral disc degeneration through inhibiting pyroptosis," *Journal of Cellular and Molecular Medicine*, vol. 24, no. 20, pp. 11742–11754, 2020.
- [26] C. Xia, Z. Zeng, B. Fang et al., "Mesenchymal stem cell-derived exosomes ameliorate intervertebral disc degeneration via anti-oxidant and anti-inflammatory effects," *Free Radical Biology & Medicine*, vol. 143, pp. 1–15, 2019.
- [27] Y. Shi, H. Shi, A. Nomi, Z. Lei-Lei, B. Zhang, and H. Qian, "Mesenchymal stem cell-derived extracellular vesicles: a new impetus of promoting angiogenesis in tissue regeneration," *Cytotherapy*, vol. 21, no. 5, pp. 497–508, 2019.
- [28] L. Wang, W. Gao, K. Xiong, K. Hu, X. Liu, and H. He, "VEGF and BFGF expression and histological characteristics of the bone-tendon junction during acute injury healing," *Journal of Sports Science and Medicine*, vol. 13, no. 1, pp. 15–21, 2014.
- [29] Y. Liu, Y. Zeng, H. B. Si, L. Tang, H. Q. Xie, and B. Shen, "Exosomes derived from human urine-derived stem cells overexpressing miR-140-5p alleviate knee osteoarthritis through downregulation of VEGFA in a rat model," *The American Journal of Sports Medicine*, vol. 50, no. 4, pp. 1088–1105, 2022.
- [30] D. Liu, G. Gu, L. Gan et al., "Identification of a CTRP9 C-terminal polypeptide capable of enhancing bone-derived mesenchymal stem cell cardioprotection through promoting angiogenic exosome production," *Redox Biology*, vol. 41, article 101929, 2021.
- [31] Y. J. Liu, H. J. Wang, Z. W. Xue et al., "Long noncoding RNA H19 accelerates tenogenic differentiation by modulating miR-140-5p/VEGFA signaling," *European Journal of Histochemistry*, vol. 65, no. 3, 2021.
- [32] S. Asai, S. Otsuru, M. E. Candela et al., "Tendon progenitor cells in injured tendons have strong chondrogenic potential: the CD105-negative subpopulation induces chondrogenic degeneration," *Stem Cells*, vol. 32, no. 12, pp. 3266–3277, 2014.
- [33] Z. K. Wang, Z. X. Wang, Z. Y. Liu, Y. Q. Ren, and Z. Q. Zhou, "Effects of RNA interference-mediated gene silencing of VEGF on the ultrafiltration failure in a rat model of peritoneal dialysis," *Bioscience Reports*, vol. 37, no. 4, 2017.
- [34] P. P. Lui, "Markers for the identification of tendon-derived stem cells in vitro and tendon stem cells in situ - update and future development," *Stem Cell Research & Therapy*, vol. 6, no. 1, p. 106, 2015.
- [35] K. Song, T. Jiang, P. Pan, Y. Yao, and Q. Jiang, "Exosomes from tendon derived stem cells promote tendon repair through miR-144-3p-regulated tenocyte proliferation and migration," *Stem Cell Research & Therapy*, vol. 13, no. 1, p. 80, 2022.
- [36] Z. Zhao, J. Liu, Z. Deng, X. Chen, and W. Li, "LncRNA MALAT1 promotes tenogenic differentiation of tendon-derived stem cells via regulating the miR-378a-3p/MAPK1 axis," *Bioengineered*, vol. 13, no. 5, pp. 13213–13223, 2022.
- [37] Y. Nakamura, S. Miyaki, H. Ishitobi et al., "Mesenchymal-stem-cell-derived exosomes accelerate skeletal muscle regeneration," *FEBS Letters*, vol. 589, no. 11, pp. 1257–1265, 2015.
- [38] J. S. Choi, H. I. Yoon, K. S. Lee et al., "Exosomes from differentiating human skeletal muscle cells trigger myogenesis of stem cells and provide biochemical cues for skeletal muscle regeneration," *Journal of Controlled Release*, vol. 222, pp. 107–115, 2016.
- [39] J. Zhang, X. Liu, H. Li et al., "Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signaling pathway," *Stem Cell Research & Therapy*, vol. 7, no. 1, p. 136, 2016.
- [40] P. Zhao, L. Xiao, J. Peng, Y. Q. Qian, and C. C. Huang, "Exosomes derived from bone marrow mesenchymal stem cells improve osteoporosis through promoting osteoblast proliferation via MAPK pathway," *European Review for Medical and Pharmacological Sciences*, vol. 22, no. 12, pp. 3962–3970, 2018.
- [41] Y. Xie, J. H. Hu, H. Wu, Z. Z. Huang, H. W. Yan, and Z. Y. Shi, "Bone marrow stem cells derived exosomes improve osteoporosis by promoting osteoblast proliferation and inhibiting cell apoptosis," *European Review for Medical and Pharmacological Sciences*, vol. 23, no. 3, pp. 1214–1220, 2019.
- [42] Y. Zhang, X. Cao, P. Li et al., "microRNA-935-modified bone marrow mesenchymal stem cells-derived exosomes enhance osteoblast proliferation and differentiation in osteoporotic rats," *Life Sciences*, vol. 272, article 119204, 2021.
- [43] S. Zhang, S. J. Chuah, R. C. Lai, J. H. P. Hui, S. K. Lim, and W. S. Toh, "MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity," *Biomaterials*, vol. 156, pp. 16–27, 2018.
- [44] Y. Wang, D. Yu, Z. Liu et al., "Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix," *Stem Cell Research & Therapy*, vol. 8, no. 1, p. 189, 2017.
- [45] J. Wu, L. Kuang, C. Chen et al., "miR-100-5p-abundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage and ameliorate gait abnormalities via inhibition of mTOR in osteoarthritis," *Biomaterials*, vol. 206, pp. 87–100, 2019.
- [46] Q. Tan, P. P. Lui, Y. F. Rui, and Y. M. Wong, "Comparison of potentials of stem cells isolated from tendon and bone marrow for musculoskeletal tissue engineering," *Tissue Engineering. Part A*, vol. 18, no. 7-8, pp. 840–851, 2012.
- [47] Y. Wang, G. He, Y. Guo et al., "Exosomes from tendon stem cells promote injury tendon healing through balancing synthesis and degradation of the tendon extracellular matrix," *Journal of Cellular and Molecular Medicine*, vol. 23, no. 8, pp. 5475–5485, 2019.
- [48] M. I. Boyer, J. T. Watson, J. Lou, P. R. Manske, R. H. Gelberman, and S. R. Cai, "Quantitative variation in vascular endothelial growth factor mRNA expression during early flexor tendon healing: an investigation in a canine model," *Journal of Orthopaedic Research*, vol. 19, no. 5, pp. 869–872, 2001.
- [49] Q. Xu, W. X. Sun, and Z. F. Zhang, "High expression of VEGFA in MSCs promotes tendon-bone healing of rotator cuff tear via microRNA-205-5p," *European Review for Medical and Pharmacological Sciences*, vol. 23, no. 10, pp. 4081–4088, 2019.